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Abstract
Some previous studies have reported that the chemokine (C-C motif) receptor 7 (CCR7) plays a role in breast
cancer, is associated with lymph node metastasis and drives the site of distant metastasis. However, the impact
of its expression on patient outcome and its association with tumour infiltrating inflammatory cells remain to be
validated. We evaluated CCR7 protein expression by immunohistochemistry in a large well characterized cohort
(n5 866) of early invasive primary breast cancers. CCR7 was expressed in the cytoplasm and membrane of
tumour cells. We observed a weak positive association of high CCR7 expression when in either cellular compo-
nent, but not both together, with axillary lymph node stage 3 tumours (p5 0.043). Logistic regression analysis
of lymph node stage revealed no independent predictive value for CCR7 expression. CCR7 expression was higher
in HER2 positive tumours (p5 0.03) and associated with positive CD681 FOXP31 tumour infiltrating cells.
CCR7 staining was negatively associated with CD31 cells. There was no significant association of CCR7 expres-
sion with breast cancer recurrence or survival. We conclude that while CCR7 is not a useful biomarker for pre-
dicting lymph node metastasis, it may reflect altered intra- and inter-cellular signalling related to the immune
microenvironment. The subcellular localization of CCR7 appears to affect the nature of these interactions.
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Introduction
Invasive breast cancer (IBC) has increasingly good
survival rates, but once metastatic disease is present,
survival rates decline sharply even in subtypes with
generally good prognosis. Determinants of metastasis
are many and varied; however, the interaction of the
tumour with the surrounding microenvironment is a
key factor that includes the activation of tumour
cell chemotaxis through specific chemoattractants in a
cell–cell or cell–matrix crosstalk. These biological
interactions are regulated in a cluster of convergent
and meticulous signalling, transcriptional, translational
and post-translational pathways [1].
Previous studies reported that the targeted migra-
tion of IBC cells toward lymphatics is stimulated by
tumour cell expression of chemokine (C-C motif)
receptor 7 (CCR7) which binds to its ligands, the
lymphoid-homing chemokines CCL19/CCL21 [2,3].
CCR7 is a protein with G-protein coupled receptor
activity that biologically functions in cellular polar-
ity, motility, and chemotaxis [4]. The expression of
CCR7 by IBC cells has been reported to promote
growth, proliferation, and metastasis of breast cancer
cells in animal models [5]. CCR7 expression has
been reported to correlate with vascular endothelial
growth factor C and the lymphatic endothelial marker
podoplanin [6]. Moreover, proliferation of blood and
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lymphatic endothelial cells through angiogenesis and
lymphangiogenesis pathways has been attributed to
actions mediated by CCR7 [6,7].
A number of studies in breast cancer cohorts have
shown that both mRNA and protein expression of
CCR7 are higher or more frequently expressed in
tumours with lymph node metastasis [8–12]. In con-
trast, analysis of the METABRIC expression data
found that this association was limited to the Luminal
B subtype (oestrogen receptor (ER) positive, high
proliferation group) [13]. Another study suggested
that COX2 expression was required for this associa-
tion to be significant [14]. Association of CCR7 with
distant metastatic sites has varied from skin [8] to
bone [15] to none [16]. These dissenting studies may
suggest that inter-cohort heterogeneity with respect to
tumour subtypes may be the reason for the lack of a
consistent association of CCR7 expression with
disease-free or breast-cancer specific survival. To
date, only a single report of an association of protein
expression with worse overall survival has been
found [11], with other studies showing at best weak
trends [8,16–18].
In this study, we aimed to resolve the association
of CCR7 with site of metastasis and patients’ breast
cancer specific survival in a large cohort of early
IBC patients with extensive clinical and molecular
characterization.
Materials and methods
Study cohort
The specimens in this study were derived from the
well-characterized Nottingham Tenovus Primary
Breast Carcinoma Series and consisted of 866 unse-
lected primary operable IBC female patients. The
detailed clinico-pathological profiles of the patients
included histological phenotype, molecular subtypes,
primary tumour size, histological grade, tumour
stage, nodal status, distant metastasis, lymphovascular
invasion and Nottingham Prognostic Index (Table 1)
[19]. Disease-free survival and breast cancer specific
survival have been recorded for up to 25 years
(median 175 months, range 1–305 months) and
include information on local and regional recur-
rences, distant metastasis and disease specific mortal-
ity. Immunohistochemistry data for a broad panel of
biomarkers is available for this cohort including ER,
HER2, Ki67, pAKT and immune-related markers
including CD68, CD3, CD8 and FOXP3 as previ-
ously published [20–23].
All experiments were conducted in compliance
with the current ethical and legal guidelines of the
United Kingdom. Ethics approval was obtained from
the Nottingham Research Ethics Committee and this
study is in accordance with the 1975 Helsinki decla-
ration and its later amendments or comparable ethical
standards.
Western blot analysis
Western blot was performed to assess the binding
specificity of rabbit monoclonal anti-CCR7 antibody
[(Y59), ab32527, Abcam, UK] to its target, residues
in the N-terminal extracellular domain. In brief, four
breast cancer cell lysates, MCF7, MDA-MB-231,
MDA-MB-468, SKBR3, together with lysates from
MCF10A (normal breast epithelial) and HeLa cells
were electrophoresed though a NuPAGE Bis-Tris
Mini Gel 4–12% (Invitrogen, UK) with MOPS SDS
Table 1. Clinico-pathologicial characteristics of the cohort
(n5 866)
Feature N %
Age
 50 years 303 35.0
> 50 years 563 65.0
Tumour size
 20 mm 413 47.7
> 20 mm 453 52.3
Grade
1 130 15.0
2 298 34.5
3 436 50.5
Stage
1 538 62.1
2 255 29.4
3 71 8.2
Tumour type
Ductal no special type 738 85.2
Classical Lobular 74 8.5
Medullary-like 20 2.3
Tubular/Mucinous 22 2.5
Others 12 1.4
ER status
Negative 211 24.4
Positive 651 75.2
Not available 4 0.5
HER2 status
Negative 720 83.1
Positive 122 14.1
Not available 24 2.8
IHC subtype
HER2 (ER2, HER21) 58 6.7
LUMA (ER1, Ki67 low, HER22) 203 23.4
LUMB (ER1, Ki67 high or HER21) 348 40.1
NEG (ER2, HER22) 144 16.6
ER1 no Ki67 data 102 11.7
ER1, Ki67 high, HER2- 280 32.2
Any HER21 121 13.9
Not available 13 1.5
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Running Buffer (Invitrogen, UK), and drops of anti-
oxidant reagent, NuPAGE Anti-Oxidant (Invitrogen,
UK) for 90 min at 150 V. Following transfer to the
membrane for 60 min at 30 V, 5% of Marvel Milk in
washing buffer PBS-Tween 20 (0.1%) was used as
the blocking buffer for 60 min.
Anti-CCR7 antibody was applied at 1:5000 in
blocking buffer; mouse monoclonal anti-bactin pri-
mary antibody was used as a marker of endogenously
expressed control. The primary antibody was incu-
bated for 12 h. Fluorescent secondary antibodies, anti-
rabbit and anti-mouse (Odyssey, Lot#C20926-02,
Lot#C20919-01) were used at 1:2000. The multiplexed
images of the detected bands were visualized using
the infrared imaging system of Li-Cor Biosciences,
Odyssey (Figure 1).
Immunohistochemistry
The immunostaining procedure was performed using
Novocastra NovolinkTM Polymer Detection Systems
kit (Code: RE7280-K, Leica, Biosystems, UK) on 4
mm thick formalin fixed paraffin-embedded of full-
face (n5 15) and tissue microarray (TMA) sections.
Sections were incubated for 1 hour with the anti-
CCR7 antibody [(Y59), ab32527, Abcam, UK]
diluted at 1:5000 using Bond Primary Antibody Dilu-
ent (Ref#AR9352, Leica, Biosystems, UK). The
bound anti-CCR7 antibody was chemically chained
with NovolinkTM Polymer, anti-rabbit Poly-HRP-IgG
[<25 lg/mL] containing 10% [v/v] animal serum in
tris-buffered saline (0.09%) ProClinTM 950, for 30
min. Finally, DAB chromogen reagent, 1.74% w/v
3,30-diaminobenzidine, in a stabilizer solution, was
added for 5 min, and followed by the addition of
0.1% Haematoxylin as a counter stain.
Scoring of CCR7 expression
High resolution digital images (Nanozoomer; Hama-
matsu Photonics, Welwyn Garden City, UK) scanned
at 320 magnification were used to facilitate scoring
of the TMA cores using the NDP.view2 software
(Hamamatsu Photonics, Systems Division). Four dif-
ferent staining intensities for CCR7 (0, 1, 2 and 3)
were given for the invasive cancer cells within the
evaluated TMA cores (Figure 2). The expression of
CCR7 was assessed semi-quantitatively using the
histo-score (H-score) method. Staining intensity was
multiplied by the percentage of representative cells in
the tissue for each intensity, producing a range of
values between 0 and 300 [24]. Two independent
observers (Sonbul S and Mukherjee A) performed the
assessment, and major discrepancies were rescored
by both scorers using a double-headed microscope.
The cut-off point, for either cytoplasmic or membra-
nous expression, used was chosen based on the
median H-score: negative/low 120 and positive
>120 H-score. A summed H-score was used to eval-
uate total CCR7 expression, with a threshold of 240.
Statistical analysis
Cohen’s kappa coefficient of agreement tests was
used as appropriate with a value below 0.75 consid-
ered to be a weak agreement between the scores of
both observers. Chi-square was used in the analysis
of the categorical CCR7 levels in relationship to
Figure 1. Validation of the anti-CCR7 antibody. Western blot-
ting showing specific antigen-binding of the anti-CCR7 primary
antibody in the cell line lysates of: MCF7, lane 1, SKBR3, lane
2, MDA-MB-231, lane 3, MDA-MB-468, lane 4, HeLa, lane 5
and MCF10A, lane 6. (A) CCR7 protein at the expected molecu-
lar weight of 42.87 kDa, visualized in lanes 1–6 as green fluo-
rescent bands in the 800 channel of the Odyssey Imaging
System. (B) b-actin protein at the expected molecular weight of
42 kDa visualized in lanes 1–6 as red fluorescent bands in the
700 channel of Odyssey Imaging System. (C) Multiplexed image
of both anti-rabbit and anti-mouse secondary antibodies used
in (A) and (B). The yellow bands indicate the overlapping pro-
teins with molecular weight around 42 kDa. The molecular
weight marker has both red and blue colored bands.
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clinical and molecular variables. For all tests, a two-
tailed P value of <0.05 was considered as signifi-
cant. Analyses were performed using SPSS (Chicago,
IL, USA). Logistic regression and survival analyses
were performed in R using glm, stepAIC (stepwise
Akaike Information Criterion model selection) and
coxph. CCR7 was considered as both a categorical
variable using the median threshold above, and also
by the continuous H-score data.
Results and discussion
Immunohistochemistry and clinico-pathological
associations
Evaluation of the CCR7 antibody using Western
analysis showed highly specific detection of the pro-
tein at the expected size of 42.87 kDa (Figure 1). In
the tumour-associated normal epithelial breast cells,
Figure 2. Immunohistochemical staining patterns of CCR7 in normal and malignant breast tissue. Immunostaining of TMA slides showing
subcellular localization of CCR7 with cytoplasmic and membranous expression: (A) normal breast terminal duct lobular units. Invasive breast
cancer with: (B) negative cytoplasmic expression, (C) negative membrane expression, (D) low cytoplasmic expression, (E) low membrane
expression, (F) positive cytoplasmic expression, (G) positive membrane expression. Objective magnifications are 310 (left) and 320 (right).
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moderate cytoplasmic staining was observed. Staining
of full-face sections in 15 IBC cases revealed homog-
enous expression of CCR7 when present (supplemen-
tary material, Figure S1); hence, the applicability of
using TMAs was validated. In the malignant cells,
CCR7 staining was observed as membranous and
cytoplasmic staining and each was scored independ-
ently. No nuclear staining was observed. In these 15
cases a very few tumour infiltrating lymphocytes
(<1%) with moderate to weak CCR7 expression
were observed (supplementary material, Figure S1).
Positive cytoplasmic expression of CCR7 (H-score
>120) was observed in 407/866 (47%) of tumours,
and only 27/866 (3%) were entirely negative. In
contrast, 99/866 tumours (11%) were negative for
membrane staining and 410/866 (47%) positive
(H-score> 120). There was a positive correlation
between cytoplasmic and membrane staining (r25
0.38, p< 0.001, Pearson correlation). 40% of cases
had low or negative staining for both compartments,
13% had positive cytoplasmic staining only, 13% had
positive membrane staining only and the remaining
34% had positive staining in both.
Few statistically significant associations were
observed between CCR7 protein levels and clinico-
pathological features for total staining, cytoplasmic
staining, membrane staining or the combination of
both (Tables 2–4; supplementary material, Table S1).
High cytoplasmic staining was associated with
younger patient age at presentation (p5 0.026), while
low staining in both compartments was associated
with lower tumour grade (p5 0.026).
Surprisingly, there was no association between
CCR7 expression and axillary nodal stage even when
binarized into lymph node positive and negative
cases. Given this contrast with the literature, we eval-
uated whether our threshold selection may have influ-
enced the results. The distribution of H-scores
between lymph node negative (stage 1) and lymph
node positive (stage 2 and 3) cases was not different
(Figure 3, p5 0.93 and p5 0.82, Kolmogorov–
Smirnov test for cytoplasmic and membrane CCR7
Table 2. Statistical associations of CCR7 cytoplasmic expression with clinico-pathological parameters
Negative/Low CCR7 Positive CCR7
Parameter N (%) N (%) v2 P value
Age (years)
 50 145 31.6 158 38.8 4.96 0.026
> 50 314 68.4 249 61.2
Size (mm)
 20 207 45.1 206 50.6 2.63 0.105
> 20 252 54.9 201 49.4
Axillary nodal stage
1 283 61.8 255 62.8 2.60 0.273
2 131 28.6 124 30.5
3 44 9.6 27 6.7
Grade
1 69 15.1 61 15.0 1.865 0.394
2 167 36.5 131 32.3
3 222 48.5 214 57.7
Distant metastasis
Yes 174 38.2 253 37.4 0.056 0.813
No 282 61.8 151 62.6
Tumour histological type
Invasive Ductal NST 384 83.7 354 87.0 3.89 0.42
Lobular 45 9.8 29 7.1
Medullary-like 13 2.8 7 1.7
Tubular/mucinous 12 2.6 10 2.5
Others 5 1.1 7 1.7
IHC subtype
HER2 (ER2, HER21) 25 6.2 33 9.5 3.17 0.37
LumA (ER1, Ki67 Low) 112 27.7 91 26.1
LumB (ER1, KI67 High or HER21) 187 46.2 161 46.3
Negative (ER2, HER22) 81 20.0 63 18.1
HER2 status
HER21 (ER1 or ER2) 51 11.4 71 18 7.844 0.009
HER22 (ER1 or ER2) 397 88.6 324 82.0
Values in bold represent values below the threshold of statistical significance; 0.05.
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respectively) suggesting that selection of the median
H-score as a cut-off point was not the cause. Interest-
ingly, when we looked at the association of CCR7
with nodal stage by cellular compartment, we found
that either membrane or cytoplasmic, but not both
together, were associated with stage 3 cases only
(p5 0.043). While 39% of stage 3 cases were posi-
tive for either and 18% positive for both, only 23%
of stage 1 cases were positive for either but 35% for
both. CCR7 was not different in stage 2 cases (Figure
3). In terms of metastatic site, there were trends for
lower cytoplasmic expression in cases with bone
metastases (p5 0.06) and for higher membrane stain-
ing in cases with liver metastases (p5 0.06). Thus,
high CCR7 was only associated with advanced breast
cancer lymph node metastases (more than three nodes
affected) and only when the CCR7 was located in a
singular compartment. Indeed, the presence of CCR7
in both sub-cellular compartments was not associated
with metastatic spread.
We subsequently performed logistic regression
analysis to evaluate whether CCR7 would predict
lymph node status, given other confounding features
such as grade, tumour size, ER status, HER2 status
and/or tumour molecular subtype. Only grade and
tumour size were consistently included as significant
factors in the model; CCR7 staining was not signifi-
cantly independent, regardless of which sub-cellular
component was considered.
We then investigated whether tumour molecular
subtype could be related to CCR7 staining using the
St Gallen recommendations for estimating intrinsic
subtype based on IHC of ER, HER2 and Ki67 (in
which Luminal B includes HER2 positive cases, [25]).
Using this system, no association of CCR7 staining
and subtype was identified (Tables (2–4)). However,
when HER2 positive cases were considered as a sepa-
rate group, there was some significant enrichment in
higher staining for CCR7 [Tables 2, 4; p5 0.009
(cytoplasmic), p5 0.03 (both membrane and cytoplas-
mic), HER21 vs. all others]. This association may be
related to the location of CCR7 near the HER2 ampli-
con on 17q and is consistent with mRNA analysis in
the METABRIC cohort [13]. When subgroup analysis
of axillary lymph node stage was performed, CCR7
combined staining was significantly associated with
Table 3. Statistical associations of CCR7 membrane expression with clinico-pathological parameters
Negative/Low CCR7 Positive CCR7
Parameter N (%) N (%) v2 P value
Age (years)
 50 150 32.9 153 37.3 1.856 0.17
> 50 306 67.1 257 62.7
Size (mm)
 20 216 47.4 197 48.0 0.04 0.84
> 20 240 52.6 213 52.0
Axillary nodal stage
1 282 62.0 256 62.6 2.921 0.23
2 129 28.4 126 30.8
3 44 9.7 27 6.6
Grade
1 79 17.4 51 12.5 4.682 0.096
2 258 34.7 140 43.2
3 218 47.9 218 53.3
Distant metastasis
Yes 171 37.7 154 37.8 0.001 0.98
No 282 62.3 253 62.2
Tumour histological type
Invasive ductal NST 386 84.6 352 85.9 2.57 0.63
Lobular 37 8.1 37 9.0
Medullary-like 11 2.4 9 2.2
Tubular/mucinous 15 3.3 7 1.7
Others 7 1.5 5 1.2
IHC subtype
HER2 (ER2, HER21) 27 6.7 31 8.8 5.136 0.16
LumA (ER1, Ki67 Low) 121 30.1 82 23.4
LumB (ER1, KI67 High or HER21) 177 44.0 171 48.7
Negative (ER2, HER22) 77 19.2 67 19.1
HER2 status
HER21 (ER1 or ER2) 56 12.6 66 16.6 2.49 0.115
HER22 (ER1 or ER2) 390 87.4 331 83.4
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stage in Luminal A (p5 0.008) and Luminal B
(p5 0.009) cases, and also HER2 negative cases
(ER2 and ER1, p5 0.01). Each group reflected the
same pattern as seen for all subtypes together. Mem-
brane staining alone was inversely significantly associ-
ated with stage within the Luminal B tumours only
(p5 0.008). This result contrasts with an analysis of
the METABRIC study data, where the only significant
association of lymph node status and CCR7 mRNA
expression was a positive correlation in the Luminal B
subtype [13]. However, in the subset of cases for
which we have both mRNA and IHC data (n5 144,
as part of the METABRIC study), mRNA and protein
H-score did not correlate (Spearman r< 0.02 for all
compartments).
Our data indicate that CCR7 is more often highly
expressed in HER2 positive tumours, and also that
low expression of CCR7 in both compartments is
weakly associated with low grade. Additionally, in
our unselected cohort, both HER2 positivity and
high grade were positively correlated with axillary
lymph node positivity (p5 0.03 and p< 0.001,
respectively). Consequently, it is possible that
previously observed strong associations of CCR7
with lymph node status may be due to selection of
cases with a biased proportion of HER2 positivity or
high grade in the lymph node positive cases. Indeed,
of the four previous IHC studies of CCR7, two
selected even numbers of lymph node positive and
lymph node negative cases without matching for
molecular subtype or tumour grade [9,11], a third
used a small unselected set but did not provide
either grade or HER2 data [10], and a final study
did not observe any CCR7 staining in tumour epi-
thelial cells [18]. The largest of these studies had
just over 200 cases, which is insufficient for sub-
group analysis, unlike our cohort.
Association of CCR7 localization and cell
signalling interactions
The subcellular localization of CCR7 is critical to its
function. In several different immune cell types
CCR7 is primarily localized to the plasma membrane
as a G-protein coupled receptor. After ligand stimula-
tion with CCL19 or CCL21 it undergoes endocytosis,
Table 4. Statistical associations of combined CCR7 cytoplasmic and membrane expression with clinico-pathological parameters
Parameter Both low Memb high Cyto high Both high v2 P value
Age (years)
 50 112 33 38 120 6.277 0.099
> 50 235 79 71 178
Size (mm)
 20 161 46 55 151 3.596 0.31
> 20 186 66 54 147
Axillary nodal stage
1 220 63 62 193 12.993 0.043
2 96 35 33 91
3 30 14 14 13
Grade
1 62 7 17 44 14.37 0.026
2 128 39 30 101
3 156 66 62 152
Distant metastasis
Yes 125 49 46 105 3.998 0.26
No 220 62 62 191
Histological tumour type
Invasive ductal NST 292 92 94 260 10.23 0.60
Lobular 32 13 5 24
Medullary-like 9 4 2 5
Tubular/mucinous 10 2 5 5
Others 4 1 3 4
IHC subtype
HER2 (ER2, HER21) 17 8 10 23 11.46 0.25
LumA (ER1, Ki67 Low) 95 17 26 65
LumB (ER1, KI67 High or HER21) 113 54 44 117
Negative (ER2, HER22) 61 20 16 47
HER2 status
HER21 (ER1 or ER2) 35 16 21 50 8.803 0.032
HER22 (ER1 or ER2) 303 94 87 237
Values in bold represent P values below the threshold of the statistical significance; 0.05.
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but is then recycled back to the membrane [26].
Membrane-associated CCR7 has been shown to be
linked to an active chemotactic response, including
to macrophages [27] and T lymphocytes. CCR7 pos-
itivity has previously been associated with high
intra-tumoural FOXP31 cells in gastric cancer, and
both proteins were associated with lymph node metas-
tasis and worse survival [28]. In this study, we also
saw positive associations between high CCR7 mem-
brane and also total CCR7 expression and the pres-
ence of FOXP31 tumour infiltrating cells in the
adjacent stroma (p5 0.002, p5 0.004 respectively) as
well as a trend for higher intra-tumoural FOXP31
cells (p5 0.07, p5 0.05). Intra-tumoural CD681 cells
were also present in higher numbers in tumours where
CCR7 was highly expressed at the membrane
(p5 0.007). CCR7 positivity was not associated with
higher CD201 or CD81 cells. We previously showed
that high numbers of CD681 or FOXP31 cells are
associated with worse prognostic factors [21,22].
Although correlative, these data suggest an interaction
between tumour membrane CCR7 expression and the
recruitment of macrophages and T regulatory lympho-
cytes within the tumour microenvironment.
In contrast to membrane localization, cells with
only cytoplasmic CCR7 do not respond to CCL19/
CCL21 stimulation, and yet here and in other cancer
types high CCR7 expression in the cytoplasm alone
is often observed. It has been suggested that this type
of expression may reflect a specific role for cytoplas-
mic CCR7 that is independent of a chemotactic inter-
action [29]. Cytoplasmic CCR7 staining and total
CCR7 staining were inversely associated with the pres-
ence of CD31 cells in the distant stroma (p5 0.01,
p5 0.006 respectively), and this association was
strengthened when considering only ER2HER22
tumours (p5 0.006). In this latter subgroup, 83% of
CCR7 cytoplasm-low cases were CD31 positive in the
distant stroma, in contrast to 59% of CCR7 positive
cases. In addition, all ER2HER22 cases with low
total CD31 counts were positive for CCR7 cytoplas-
mic staining. Thus, cases with CCR7 cytoplasmic
staining may be enriched for a subgroup of
ER2HER22 with a low T-lymphocyte response.
Figure 3. CCR7 expression is not related to lymph node status. Histogram of CCR7 (A) cytoplasmic and (B) membrane staining H-
scores as a percentage of cases that are lymph node negative (blue) or lymph node positive (green). (C) Percentage of cases with
high CCR7 staining across different cellular compartments (cytoplasmic, membrane or both) and association with axillary lymph node
stage (15 no positive nodes, 25 1–3 positive nodes, 35more than 3 positive nodes).
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For cells with both high membrane and cytoplas-
mic CCR7 staining, we observed a counter-intuitive
negative association with axillary nodal stage 3 cases.
Other studies in different cancer types have not to
date separated cases by subcellular localization of
CCR7 staining. Therefore, it is unclear what such
high expression in multiple cellular components may
mean functionally for a tumour cell. We speculate that
such staining may in some cases indicate an aberrant
pattern whereby the usual trafficking of CCR7 between
the membrane and the cytoplasm has been compro-
mised. In HEK293 cells, expression of a CCR7 cDNA
lacking lysine residues critical for ubiquitylation
delayed recycling of the protein from endosomes back
to membrane after ligand stimulation. CCR7 protein
was observed to accumulate in the Golgi network, and
this impaired recycling led to a defect in migratory
chemokine response [30]. Such abnormal trafficking
may represent a cellular context that does not provide
a selective advantage for lymph node metastasis. This
hypothesis could be tested by performing a similar
CCR7 over expression experiment in breast cancer
cells both in vitro (assessing chemokine response) and
in vivo (evaluating metastatic potential).
Survival analysis
In order to assess any effect of CCR7 on patient sur-
vival, we performed Akaike Information Criterion analy-
sis using axillary nodal stage, tumour grade, tumour
size, ER status and HER2 status as factors in the model
along with the CCR7 H-score. In both disease-free and
breast-cancer specific survival, CCR7 membrane stain-
ing or a combined H-score summing cytoplasmic and
membrane staining were included in the final models, as
was CCR7 cytoplasmic staining for disease-free survival
(see supplementary text). Similar results were obtained
when CCR7 staining was input as a categorical variable.
These results suggested that CCR7 protein expression
added independent prognostic information to the survival
model. However, when the Cox regression output was
examined, this contribution was not significant at a
p< 0.05 level, indicating that the effect of CCR7 protein
expression is small and dependent on other factors. This
borderline association of CCR7 with survival suggests
that the previous conflicting studies would have been
likely influenced by sample selection, nudging the
results into significance in certain small cohorts.
In conclusion, we do not find strong evidence to sug-
gest that CCR7 protein is a useful biomarker of lymph
node metastasis, disease free recurrence or breast-
cancer specific survival. However, we do find a link
with high axillary node stage and specific subcellular
localization of CCR7. While there was a correlation
between CCR7 and HER2 positivity, the molecular
subtype analyses enabled by our large cohort did not
find any significant associations with survival when
performed within subgroups. However, CCR7 was
associated with altered tumour microenvironment,
which may influence tumour capacity to spread through
the lymphatic system. The association depends upon
the subcellular localization of CCR7, with membrane
staining showing an association with the presence of
macrophages and regulatory T cells, whereas cytoplas-
mic staining was associated with CD31 T cells. These
associations require functional validation, for example
by exogenous expression of various mutated forms of
CCR7, with defective membrane or cytoplasmic local-
ization, in an immune competent mouse model system
of breast cancer to evaluate the impact on the tumour
immune microenvironment. The distinct roles of CCR7
at the membrane and the cytoplasm deserve further
attention, particularly in a cancer context.
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Supplementary Text. Results of Akaike Information Criterion analysis
Table S1. Statistical associations of total CCR7 cytoplasmic and membrane expression with clinico-pathological parameters
Figure S1. Full face staining of CCR7 in IBC shows homogenous patterns of positivity. Marginal low expression of CCR7 was detected in a
few lymphocytes (<1%), red arrows. (A) at 4x (B) at 10x, (C) at 20x, and (D) at 40x magnification power
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